We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ARTH market cap is 5.36M. The company's latest EPS is USD -1.4725 and P/E is -0.77.
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 12k | 16k | 76k |
| Operating Income | -6.37M | -5.37M | -6.39M | -5.71M | -5.04M |
| Net Income | -4.55M | -4.69M | -6.25M | -5.28M | -6.98M |
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.9M | 2.15M | 3.68M | 2.6M | 1.96M |
| Total Liabilities | 3.71M | 3.65M | 4.7M | 6.8M | 9.47M |
| Total Equity | -807k | -1.5M | -1.03M | -4.19M | -7.51M |
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -5.27M | -5.05M | -5.96M | -4.46M | -3.37M |
| Investing | N/A | -2k | -3k | N/A | -5k |
| Financing | 2.78M | 3.83M | 7.27M | 2.94M | 2.86M |
| Market Cap | 5.36M |
| Price to Earnings Ratio | -0.77 |
| Price to Sales Ratio | 70.63 |
| Price to Cash Ratio | 24.04 |
| Price to Book Ratio | -0.71 |
| Dividend Yield | - |
| Shares Outstanding | 4.74M |
| Average Volume (1 week) | 1.32k |
| Average Volume (1 Month) | 2.46k |
| 52 Week Change | -62.33% |
| 52 Week High | 18.00 |
| 52 Week Low | 0.39 |
| Spread (Intraday) | 0.38 (26.21%) |
| Company Name | Arch Therapeutics Inc (QB) |
| Address |
769 basque way carson city, nevada 89706 |
| Website | https://www.archtherapeutics.com |
| Industry | surgical,med instr,apparatus (3841) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
